Amgen is the world's largest and most successful biotech company.
安进公司是世界上最大最成功的生物科技公司。
He cites in evidence a drug trial by Amgen, a biotech giant, where the researchers concluded that the drug was not effective.
Grove博士举出了这样的一个例子：那是一个由生物技术界的巨头——安进公司所进行的一项药品实验。在这项实验里，研究人员总结道，该药品并不有效。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Since then, Amgen has sold more than $25 billion of Epogen, including $2.5 billion last year.
从那个时候开始，安进销售了超过250亿美元的Epogen，包括去年的25亿。
Amgen said it was pleased with the verdict and would seek an injunction to prevent Roche from releasing Mircera in the United States.
安进声称满意判决，并将寻求禁令以阻止罗氏在美国发布Mircera。
A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent.
一次联邦审判认定Mircera，一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物，触犯了安进的专利权。
Amgen said it would present some new evidence, including information showing that more cancer patients are now needing blood transfusions.
安进表示将提供一些新的证据，包括如今需要输血的癌症患者正在增多等信息。
Iressa from AstraZeneca and Vectibix from Amgen are among EGFR blockers now available to treat colorectal, lung, breast and other cancers.
阿斯利康公司的Iressa和Amgen公司的Vectibix是目前用于临床治疗结直肠肿瘤、肺癌、乳腺癌和其他肿瘤的EGFR拮抗剂。
Amylin Pharmaceuticals Inc. of San Diego, which bought the rights to leptin from Amgen Inc. in 2006, is testing it, in combination with pramlintide, a diabetes drug.
圣地亚哥的Amylin PharmaceuticalsInc。于2006年从Amgen Inc。购买了瘦素的专利权，目前正在对瘦素和糖尿病药物普兰林（月太）联合作用的效果进行试验。
Because some patents were not granted until years after Amgen applied, the patent protection could extend until 2015, longer than the 20 years contemplated by patent law.
由于一些专利在安进公司申请后好几年还没有被批准，因此这个专利保护将延长到2015年，超过了专利法规定的20年。
A jury in Federal District Court in Boston ruled that Roche's new drug, Mircera, infringed on three Amgen patents and upheld the validity of those patents and two others.
一个波士顿的联邦地区法庭陪审团判定罗氏的新药Mircera侵犯了三项安进公司专利，并且确定这些专利和其他两项专利的有效性。
A jury in Federal District Court in Boston ruled that Roche's new drug, Mircera, infringed on three Amgen patents and upheld the validity of those patents and two others.
一个波士顿的联邦地区法庭陪审团判定罗氏的新药Mircera侵犯了三项安进公司专利，并且确定这些专利和其他两项专利的有效性。
应用推荐